UAE and Saudi Arabia: Gateways to International Biopharma Markets Biopharmaceutical companies like Sanofi, AbbVie, and Virax Biolabs are capitalizing on lucrative business opportunities in the Middle East, particularly in the United Arab Emirates (UAE) and Saudi Arabia. These countries have become attractive markets for cutting-edge therapies, driven by their growing populations with a rising in..
Despite the challenging economic climate, the life science industry has witnessed a total of seven significant IPOs in 2023. However, when compared to previous years, it is clear that there is still a drought in IPO activity within the industry. In 2022, there were only 47 biotech IPOs, raising approximately $4 billion. This marks a significant decrease from 2021, which saw 152 offerings raising..
the potential of their Flow Electroporation® technology and ExPERT™ platform in the field of gene-edited cell therapeutics. By allowing Vittoria to utilize their innovative technology, MaxCyte is enabling the development and production of cutting-edge gene-edited cell therapies for T-cell lymphoma. Vittoria's lead program, Viper 101, is a promising gene-edited cell therapy specifically designed ..
16">The study aims to determine the effectiveness of SerpinPC in reducing bleeds in individuals with hemophilia B. Hemophilia B is a rare genetic disorder that affects the blood's ability to clot properly, leading to prolonged bleeding and increased risk of complications. Current treatment options for hemophilia B include regular infusions of clotting factors, but these can be costly and time-co..
AIM ImmunoTech Inc. (NYSE American: AIM) has commenced its Phase 2 study to evaluate the potential therapeutic effects of Ampligen® on individuals with post-COVID conditions. The enrollment and dosing of the first subject have already taken place, with encouraging preliminary data on Ampligen. The study is projected to be fully enrolled by Q4 2023. In order to facilitate this study, AIM has esta..
Tango Therapeutics, a clinical-stage biotechnology company, has recently announced an important milestone in their research. The first patient has been dosed in the phase 1/2 trial of TNG462, a potential treatment for patients with MTAP-deleted solid tumors. This trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG462. Notably, the drug has received Fast Track..
